Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53887989&newsitemid=20240125010746&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=cf95f538467bf030653f44a88e59a7b4)) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID® [Immune Globulin Infusion (Human) 10% solution] as an intravenous immunoglobulin (IVIG) therapy to improve neuromuscular disability and impairment in …